A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3)
Status:
Recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo controlled, Randomized Study to
Evaluate the Efficacy and Safety of AUR101 in patients with Moderate-to-Severe Psoriasis
(INDUS-3)